<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-100915</identifier>
<setSpec>1888-6116</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Traumatic brain injury: failure of the intravenous route for the administration of bone marrow stromal stem cells as treatment of chronic neurological sequels</dc:title>
<dc:creator>Zurita, M</dc:creator>
<dc:creator>Bonilla, C</dc:creator>
<dc:creator>Aguayo, C</dc:creator>
<dc:creator>Rico, M</dc:creator>
<dc:creator>Rodríguez, A</dc:creator>
<dc:creator>Otero, L</dc:creator>
<dc:creator>Vela, A</dc:creator>
<dc:creator>Vaquero, J</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">Objective: We studied the possible therapeutic effect of intravenous administration (noninvasive method) of BMSCs to treat neurological sequels in a chronic stage after TBI. Material and method: A model of TBI in adult Wistar rats was performed and we studied the neurological deficit induced in the course of two months, through the mNSS and Smart tests. After this time, with established sequels, 15 x 106 BMSCs (n = 10) or saline (n = 10) were administered intravenously. Changes in the neurological deficits were studied in two months. Results: Comparison of functional changes between both experimental groups showed no statistically significant differences. Conclusions: Our results suggest that transplantation of BMSCs intravenously, at a stage of established sequels after severe TBI, has no therapeutic effect (AU)</dc:description>
<dc:source>Trauma (Majadahonda);23(2): 114-122, abr.-jun. 2012. tab, ilus</dc:source>
<dc:identifier>ibc-100915</dc:identifier>
<dc:title xml:lang="es">Daño cerebral traumático: fallo de la vía intravenosa para la administración de células madre estromales de médula ósea como tratamiento de las secuelas neurológicas crónicas</dc:title>
<dc:subject>^d1956^s22075</dc:subject>
<dc:subject>^d28599</dc:subject>
<dc:subject>^d34226^s22075</dc:subject>
<dc:subject>^d34226^s22067</dc:subject>
<dc:subject>^d1878^s22042</dc:subject>
<dc:subject>^d1956^s22067</dc:subject>
<dc:subject>^d7697^s22073</dc:subject>
<dc:subject>^d13620^s22031</dc:subject>
<dc:subject>^d21030</dc:subject>
<dc:subject>^d13620^s22044</dc:subject>
<dc:subject>^d841</dc:subject>
<dc:subject>^d12345</dc:subject>
<dc:subject>^d54271</dc:subject>
<dc:subject>^d32367^s22073</dc:subject>
<dc:subject>^d34226^s22016</dc:subject>
<dc:subject>^d1956^s22016</dc:subject>
<dc:type>article</dc:type>
<dc:date>201206</dc:date>
</metadata>
</record>
</ibecs-document>
